Biomarkers of hypoxic-ischemic encephalopathy in newborns.
Biomarkers of hypoxic-ischemic encephalopathy in newborns.
复制标题
DOI：
10.3389/fneur.2012.00144
复制
发表时间：
2012
影响因子：
3.4
通讯作者：
Weiss MD
中科院分区：
文献类型：
--
作者：
Douglas-Escobar M;Weiss MD
随着新生儿重症监护的发展，重点已从单纯提高死亡率转向努力提高死亡率和发病率。新生儿脑损伤最常见的来源是缺氧缺血性损伤。1,000名足月婴儿中约有2名发生缺氧缺血性损伤，严重损伤的婴儿将终身残疾和神经发育迟缓。最近，随着治疗性低温的出现，神经保护方面的显着努力已经开始，新生儿神经保护发展的关键一步是发现生物标记物，使临床医生和科学家能够筛查婴儿的脑损伤，监测疾病的进展，识别受损的大脑区域，并评估神经保护临床试验的效果。最后，生物标记物为确定损伤发生的时间提供了极大的希望，有助于揭示潜在的病理生理学和最有效的治疗方法。本文就S100B、神经元特异性烯醇化酶、脐带IL-6、CK-BB、GFAP、髓鞘碱性蛋白、UCHL-1、pNF-H等HIE生物标志物的研究进展作一综述。我们希望对已建立的和新的新生儿脑损伤生物标志物的认识、验证和临床应用做出贡献。
As neonatal intensive care has evolved, the focus has shifted from improving mortality alone to an effort to improve both mortality and morbidity. The most frequent source of neonatal brain injury occurs as a result of hypoxic-ischemic injury. Hypoxic-ischemic injury occurs in about 2 of 1,000 full-term infants and severe injured infants will have lifetime disabilities and neurodevelopmental delays. Most recently, remarkable efforts toward neuroprotection have been started with the advent of therapeutic hypothermia and a key step in the evolution of neonatal neuroprotection is the discovery of biomarkers that enable the clinician-scientist to screen infants for brain injury, monitor progression of disease, identify injured brain regions, and assess efficacy of neuroprotective clinical trials. Lastly, biomarkers offer great hope identifying when an injury occurred shedding light on the potential pathophysiology and the most effective therapy. In this article, we will review biomarkers of HIE including S100B, neuron specific enolase, umbilical cord IL-6, CK-BB, GFAP, myelin basic protein, UCHL-1, and pNF-H. We hope to contribute to the awareness, validation, and clinical use of established as well as novel neonatal brain injury biomarkers.